The group's principle activity is to develop minimally invasive, biomaterials-based products intended to treat the early-stage degeneration of the spinal disc. The group's product includes DiscCell, an injectable, in-situ setting, radio-opaque, non-hydrogel polymer material that augments or replaces the diseased nucleus pulposus of the spinal disc. The group operates from United States.
Executive Information
Name
Title
Email
David Anderson
Dir., CEO, Pres.
N/A
Noel Rolon
VP - Clinical, Regulatory Affairs
N/A
Arthur Klausner
Dir.
N/A
Barry Myers
Member - Surgical Advisory Board
N/A
Charles Cohen
VP - Product Development, Member - Surgical Advisory Board
